Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Anderson

Showing results (451-460 of 474) with videos related to

Pageof 48
Sort By:
Molecular Cancer|June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cellsMareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Nature Communications|August 5, 2025
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector functionMarta Barisa, Henrike P Muller, Elisa Zappa, et al.
British Journal of Cancer|July 9, 2026
Paediatric therapeutic development workshop on medulloblastomaClaudia Montiel Equihua, Joseph S Baxter, Jan J Molenaar, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
Science Translational Medicine|November 26, 2020
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastomaKarin Straathof, Barry Flutter, Rebecca Wallace, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsAndrew D J Pearson, Claudia Rossig, Giovanni Lesa, et al.
Pageof 48

Showing results (451-460 of 474) with videos related to

Sort By:
Pageof 48
Molecular Cancer|June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cellsMareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Nature Communications|August 5, 2025
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector functionMarta Barisa, Henrike P Muller, Elisa Zappa, et al.
British Journal of Cancer|July 9, 2026
Paediatric therapeutic development workshop on medulloblastomaClaudia Montiel Equihua, Joseph S Baxter, Jan J Molenaar, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
Science Translational Medicine|November 26, 2020
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastomaKarin Straathof, Barry Flutter, Rebecca Wallace, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsAndrew D J Pearson, Claudia Rossig, Giovanni Lesa, et al.
Pageof 48